NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.66 -0.19 (-1.01 %) (As of 04/19/2019 01:00 PM ET)Previous Close$18.85Today's Range$18.62 - $19.0352-Week Range$17.42 - $24.97Volume2.63 million shsAverage Volume875,628 shsMarket Capitalization$12.83 billionP/E Ratio15.95Dividend Yield1.86%Beta1.07 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain. Receive GRFS News and Ratings via Email Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRFS Previous Symbol CUSIPN/A CIK1438569 Webwww.grifols.com Phone212-969-3335Debt Debt-to-Equity Ratio1.30 Current Ratio2.77 Quick Ratio1.22Price-To-Earnings Trailing P/E Ratio15.95 Forward P/E Ratio14.58 P/E Growth1.39 Sales & Book Value Annual Sales$5.30 billion Price / Sales2.42 Cash Flow$1.4952 per share Price / Cash Flow12.48 Book Value$8.07 per share Price / Book2.31Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$704.63 million Net Margins13.33% Return on Equity16.86% Return on Assets5.98%Miscellaneous Employees21,230 Outstanding Shares687,554,000Market Cap$12.83 billion Next Earnings Date5/2/2019 (Estimated) OptionableOptionable GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions What is GRIFOLS S A/S's stock symbol? GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS." How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S? GRIFOLS S A/S announced a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is an increase from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History. When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work? GRIFOLS S A/S's stock split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split. How were GRIFOLS S A/S's earnings last quarter? GRIFOLS S A/S (NASDAQ:GRFS) released its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter. The biotechnology company earned $1.40 billion during the quarter. GRIFOLS S A/S had a return on equity of 16.86% and a net margin of 13.33%. View GRIFOLS S A/S's Earnings History. When is GRIFOLS S A/S's next earnings date? GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for GRIFOLS S A/S. What price target have analysts set for GRFS? 6 brokers have issued 1 year price objectives for GRIFOLS S A/S's shares. Their forecasts range from $19.00 to $19.00. On average, they expect GRIFOLS S A/S's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for GRIFOLS S A/S. What is the consensus analysts' recommendation for GRIFOLS S A/S? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S. Has GRIFOLS S A/S been receiving favorable news coverage? News headlines about GRFS stock have trended very positive on Friday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GRIFOLS S A/S earned a media sentiment score of 3.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of GRIFOLS S A/S's key competitors? Some companies that are related to GRIFOLS S A/S include Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), ASTELLAS PHARMA/ADR (ALPMY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL) and Merck KGaA (MKGAF). What other stocks do shareholders of GRIFOLS S A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), NVIDIA (NVDA), Alibaba Group (BABA), Southern Copper (SCCO), Celgene (CELG), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR) and Tesla (TSLA). Who are GRIFOLS S A/S's key executives? GRIFOLS S A/S's management team includes the folowing people: Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 55)Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs Who are GRIFOLS S A/S's major shareholders? GRIFOLS S A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Mercer Global Advisors Inc. ADV (0.00%) and Huntington National Bank (0.00%). Which major investors are selling GRIFOLS S A/S stock? GRFS stock was sold by a variety of institutional investors in the last quarter, including Huntington National Bank. Which major investors are buying GRIFOLS S A/S stock? GRFS stock was acquired by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV. How do I buy shares of GRIFOLS S A/S? Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GRIFOLS S A/S's stock price today? One share of GRFS stock can currently be purchased for approximately $18.66. How big of a company is GRIFOLS S A/S? GRIFOLS S A/S has a market capitalization of $12.83 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe. What is GRIFOLS S A/S's official website? The official website for GRIFOLS S A/S is http://www.grifols.com. How can I contact GRIFOLS S A/S? GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected] MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 240 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 552MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/19/2019 by MarketBeat.com StaffFeatured Article: How Do Mutual Funds Work?